{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:43:39Z","timestamp":1770504219446,"version":"3.49.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/igc.0b013e318217b360","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T03:43:56Z","timestamp":1304394236000},"page":"S6-S8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S1","title":["Safety Profile of Trabectedin in Combination With Liposomal Pegylated Doxorrubicin in Relapsed Ovarian Carcinoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Antonio-Gonzal\u00e8z","family":"Mart\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e318217b360_bb0005","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318217b360_bb0010","first-page":"viii304","article-title":"Trabectedin has a low cardiac risk profile: a comprehensive safety analysis","volume":"21","author":"Lebedinsky","year":"2010","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e318217b360_bb0015","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/jco.2010.28.15_suppl.5121","article-title":"Tolerability of long-term use of trabectedin in combination with pegylated liposomal doxorubicin in patients with relapsed ovarian cancer","volume":"15","author":"Romero","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318217b360_bb0020","series-title":"ECCO 15 and 34th ESMO Multidisciplinary Congress","first-page":"20","article-title":"Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older","author":"Vergote","year":"2009"},{"key":"10.1097\/IGC.0b013e318217b360_bb0025","first-page":"15s","article-title":"Health-related quality of life\/patient-reported outcomes in relapsed ovar\u00edan cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone","volume":"27","author":"Kransner","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318217b360_bb0030","series-title":"13th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2010)","article-title":"Patients-reported outcomes in patients with relapsed, platinum-sensitive ovarian cancer: results from a large randomized phase III trial","author":"Vermorken","year":"2010"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24198192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24198192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e318217b360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:34:59Z","timestamp":1753101299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24198192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":6,"alternative-id":["S1048891X24198192"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e318217b360","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Profile of Trabectedin in Combination With Liposomal Pegylated Doxorrubicin in Relapsed Ovarian Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e318217b360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 IGCS and ESGO","name":"copyright","label":"Copyright"}]}}